News & articles
GLP-1 Bulk-Drug Comment Period Closes; Thousands of Filings on 503B Peptide AccessFDA logged roughly 3,900 public comments by the July 30, 2026 deadline on whether GLP-1 bulk substances belong on the 503B bulks list—one of the agency's busiest compounding dockets ever.
- FDA Advisory Panel Backs Six Peptides for 503A Bulks-List Consideration
The FDA Pharmacy Compounding Advisory Committee recommended six peptide bulk substances for 503A list consideration after two days of safety, sourcing, and dosing testimony in July 2026.
- Ketone Esters Plus Semaglutide: Preclinical Data on Muscle Preservation Draws Attention
Researchers reported in June 2026 that (R)-3-hydroxybutyl (R)-3-hydroxybutyrate ketone ester co-administration attenuated lean-mass loss in semaglutide-treated rats without blocking fat reduction.